We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · January 03, 2011

Trastuzumab-DM1 Is Effective in Pre-treated HER2+ Metastatic Breast Cancer

Journal of Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer After Prior HER2-Directed Therapy
J. Clin. Oncol 2010 Dec 20;[EPub Ahead of Print], HA Burris III, HS Rugo, SJ Vukelja, CL Vogel, RA Borson, S Limentani, E Tan-Chiu, IE Krop, RA Michaelson, S Girish, L Amler, M Zheng, YW Chu, B Klencke, JA O'Shaug

Further Reading